Epizyme Inc. buy stratec
Start price
24.09.18
/
50%
€9.70
Target price
04.11.21
€23.45
Performance (%)
-55.86%
End price
05.11.21
€4.28
Summary
This prediction ended on 05.11.21 with a price of €4.28. The BUY prediction by stratec for Epizyme Inc. performed very badly with a performance of -55.86%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Epizyme Inc. | - | - | - | - |
| iShares Core DAX® | -2.680% | 4.261% | 2.121% | 57.510% |
| iShares Nasdaq 100 | 0.725% | 5.796% | 34.204% | 92.829% |
| iShares Nikkei 225® | -0.725% | 9.319% | 61.298% | 80.340% |
| iShares S&P 500 | 1.166% | 5.479% | 24.751% | 70.967% |
Comments by stratec for this prediction
In the thread Epizyme Inc. diskutieren
stratec stimmt dem Sentiment von 'Buy' zu
Oppenheimer's call:An annoncement of the partial clinical hold being lifted by FDA supports our outlook for tazemetostat. Tazemetostat is currently being studied in clinical programs in INI-1 negative tumors, synovial sarcomas, follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and mesothelioma. While the partial clinical hold may have delayed enrollment in some studies, these are not currently factored into our outlook; therefore, the hold had little impact on our outlook. The news removes a regulatory overhang and supports our outlook for Epizyme.”
In the thread Trading Epizyme Inc.
Die von stratec gewählte maximale Laufzeit wurde überschritten